Evidence map›Paper›PMID 26621621›Full record

ArticleAntimicrobial agents and chemotherapy2016

Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.

Diansy Zincke, Deepak Balasubramanian, Lynn L Silver, Kalai Mathee

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. β-lactam Resistance inPathogens (Basel, Switzerland) · 2021
    Review
  7. Article
  8. Occurrence of NDM-1 and VIM-2 Co-ProducingDiagnostics (Basel, Switzerland) · 2021
    Article
  9. Article
  10. Article
  11. Resistance mechanisms and therapeutic strategies forTherapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Diansy ZinckeDepartment of Biological Sciences, College of Arts and Sciences, Florida International University, Miami, Florida, USA.
Deepak BalasubramanianDepartment of Biological Sciences, College of Arts and Sciences, Florida International University, Miami, Florida, USA.
Lynn L SilverLL Silver Consulting, Springfield, New Jersey, USA.
Kalai MatheeDepartment of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA matheelabfor65roses@gmail.com.
Florida International University · US

Funding

MBRS RESEARCH INITIATIVE FOR SCIENTIFIC ENHANCEMENTR25GM061347 · NIGMS · FLORIDA INTERNATIONAL UNIVERSITY · PI LICKLITER, ROBERT E · 2000 to 2016
$14.7M
Regulation of P. aeruginosa PoxB Oxacillinase by AmpR and a Two-Component SystemSC1AI081376 · NIAID · FLORIDA INTERNATIONAL UNIVERSITY · PI MATHEE, KALAI · 2008 to 2011
$1.2M
NIAID NIH HHS SC1 AI081376NIAID NIH HHS SC1AI081376NIGMS NIH HHS R25 GM061347NIGMS NIH HHS R25 GM61347
6 · The paper itself

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen often associated with severe and life-threatening infections that are highly impervious to treatment. This microbe readily exhibits intrinsic and acquired resistance to varied antimicrobial drugs. Resistance to penicillin-like compounds is commonplace and provided by the chromosomal AmpC β-lactamase. A second, chromosomally encoded β-lactamase, PoxB, has previously been reported in P. aeruginosa. In the present work, the contribution of this class D enzyme was investigated using a series of clean in-frame ampC, poxB, and oprD deletions, as well as complementation by expression under the control of an inducible promoter. While poxB deletions failed to alter β-lactam sensitivities, expression of poxB in ampC-deficient backgrounds decreased susceptibility to both meropenem and doripenem but had no effect on imipenem, penicillin, and cephalosporin MICs. However, when expressed in an ampCpoxB-deficient background, that additionally lacked the outer membrane porin-encoding gene oprD, PoxB significantly increased the imipenem as well as the meropenem and doripenem MICs. Like other class D carbapenem-hydrolyzing β-lactamases, PoxB was only poorly inhibited by class A enzyme inhibitors, but a novel non-β-lactam compound, avibactam, was a slightly better inhibitor of PoxB activity. In vitro susceptibility testing with a clinical concentration of avibactam, however, failed to reduce PoxB activity against the carbapenems. In addition, poxB was found to be cotranscribed with an upstream open reading frame, poxA, which itself was shown to encode a 32-kDa protein of yet unknown function.

Indexed as

Azabicyclo CompoundsBacterial Proteinsbeta-Lactamasesbeta-Lactam ResistanceCarbapenemsGene DeletionGene Expression Regulation, BacterialImipenemMeropenemMicrobial Sensitivity TestsOperonPorinsPseudomonas aeruginosaThienamycinsAmpC beta-lactamasesavibactamAzabicyclo CompoundsBacterial Proteinsbeta-lactamase PoxB, Pseudomonas aeruginosabeta-LactamasesCarbapenemsImipenemMeropenemOprD protein, Pseudomonas aeruginosaPorinsThienamycins

Identifiers

PMID26621621
PMCPMC4750667
OpenAlexW2184391279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.